<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066739</url>
  </required_header>
  <id_info>
    <org_study_id>UCIANES10</org_study_id>
    <nct_id>NCT03066739</nct_id>
  </id_info>
  <brief_title>Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia</brief_title>
  <official_title>Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether using ultra-low dose naloxone, an opioid
      antagonist, has the potential to block remifentanil-induced hyperalgesia and tolerance
      following surgery.

      There are 3 study groups: (1) low dose remifentanil (LO, 0.1 micrograms/kg/mL), (2) high dose
      remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL), or (3) high dose
      remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL
      naloxone).

      The hypothesis of the study is that occurrence of remifentanil-induced hyperalgesia (low
      score in mechanical pain threshold) in the HN group will be lower than in the HI group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      Opioid antagonists at ultra-low doses have been used with opioid agonists to prevent or limit
      opioid tolerance. Remifentanil, a rapid onset/offset opioid that is often used as an
      anesthesia adjunct intraoperatively, has been associated with the development of hyperalgesia
      and opioid tolerance postoperatively. Opioid-induced hyperalgesia (OIH) induced by
      remifentanil intraoperatively may be a factor contributing to an increase in postoperative
      pain as well as difficulty in controlling such pain. The purpose of this study will be to
      evaluate whether an ultra-low dose of naloxone, an opioid antagonist, could block
      remifentanil-induced hyperalgesia and tolerance following surgery.

      This research will help elucidate the degree of OIH after surgeries involving remifentanil
      and determine if a new technique can be employed to decrease remifentanil-induced OIH. By
      mitigating OIH, patients should have a decrease in postoperative pain and an increase in
      patient satisfaction at UCI and other hospitals where such a technique is employed.

      There are 3 study groups: (1) low dose remifentanil (LO, 0.1 micrograms/kg/mL), (2) high dose
      remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL), or (3) high dose
      remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL
      naloxone).

      Background:

      Opioid-induced hyperalgesia is a paradoxical increase in pain sensitivity following opioid
      exposure. The mechanism for this is likely due to an alteration in opioid receptor signaling
      with disruption of G-protein coupling and opioid-induced activation and hypertrophy of spinal
      glial cells (gliosis). Opioid-induced hyperalgesia has been noted with many different
      opioids, and the most well documented hyperalgesic effect is with remifentanil.

      Various agents have been used in an attempt to reduce the development hyperalgesia following
      remifentanil. While there are few reports on the effect of ultra-low dose naloxone on
      opioid-induced hyperalgesia, recent evidence is emerging regarding its use in pain
      management. Ultra-low dose naloxone has been shown to prevent remifentanil-induced pain
      hypersensitivities (allodynia and hyperalgesia) in rats. However, there are little to no
      studies on reducing the adverse effects of remifentanil with naloxone in human subjects.

      Existing knowledge and previous research:

      Attempts have been made with various agents to reduce the development of tolerance and
      hyperalgesia following remifentanil. Postoperative hyperalgesia and its prevention has been
      studied with ketamine , Magnesium , Gabapentin, Clonidine, Lornoxicam , Dextromethorphan ,
      Paracetamol , Morphine , Dexmedetomidine , Adenosine, COX inhibitors , Amantadine , Nitrous
      oxide, Fentanyl, Pregabalin , Buprenorphine, Midazolam, Dexamethasone. Relevant to our
      current hypothesis is the report that concomitant administration of ultra-low dose naloxone
      and naltrexone with remifentanil prevented OIH. However, there are no studies on reducing the
      adverse effects of remifentanil with ultra-low dose naloxone in human subjects.

      While the traditional role of opiate antagonists have been in cases of opioid overmedication,
      recent evidence is emerging regarding their use in pain management. Gan et al. 1997 used an
      ultra-low dose naloxone infusion (0.00025 mg/kg/h or 0.001 mg/kg/h) in postoperative patients
      receiving IV morphine via a patient-controlled analgesia (PCA) device. Good pain relief was
      experienced in all groups, however consumption of PCA morphine was significantly reduced in
      patients that received the lowest infusion of naloxone and opioid-induced side effects
      (nausea, vomiting, pruritus) were reduced by naloxone at both dose.

      Naloxone and/or naltrexone at ultra-low doses may enhance the analgesic effects of opioids,
      enhance the antinociceptive effects of methadone, and decrease or block the development of
      opioid tolerance in rodents. The combination of oxycodone with an ultra-low dose of the
      antagonist naltrexone as a singular oral medication, Oxytrex, has been developed to prevent
      the development of tolerance in the treatment of moderate to severe chronic pain.

      Aguado et. al. 2013 recently evaluated the effects of the opioid antagonist, naloxone, on
      remifentanil-induced tolerance or hyperalgesia in rats. Hyperalgesia was considered to be a
      decrease in mechanical nociceptive thresholds (von Frey), while opioid tolerance was
      considered to be a decrease in sevoflurane MAC reduction by remifentanil. An ultra-low dose
      of naloxone was able to block remifentanil-induced hyperalgesia and the MAC increase
      associated with hyperalgesia, but did not change opioid tolerance under inhaled anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Opioid-induced hyperalgesia (OIH)</measure>
    <time_frame>24 hr Post-surgery</time_frame>
    <description>Mechanical Pain Threshold-determined by von Frey filaments around the incision site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Opioid-induced hyperalgesia (OIH)</measure>
    <time_frame>48 hr Post-surgery</time_frame>
    <description>Mechanical Pain Threshold-determined by von Frey filaments around the incision site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>24 hr post surgery</time_frame>
    <description>Opioid consumption required to control pain by Oral morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>48 hrs post surgery</time_frame>
    <description>Opioid consumption required to control pain by Oral morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold Pressure Test</measure>
    <time_frame>24 hr post surgery</time_frame>
    <description>Pain Threshold and Pain tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold Pressure Test</measure>
    <time_frame>48 hrs post surgery</time_frame>
    <description>Pain Threshold and Pain tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain scores</measure>
    <time_frame>Baseline</time_frame>
    <description>VAS pain scores measured prior to surgery and at 4, 8 and 12h after extubation and again at 24h and 48h post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>McGill short form questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>The McGill questionnaire provides an assessment of pain quality and descriptors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>Baseline</time_frame>
    <description>Brief Pain Inventory assesses both pain intensity and pain unpleasantness (the emotional component of pain is considered to be a better metric of subject satisfaction and quality of life).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Hyperalgesia</condition>
  <arm_group>
    <arm_group_label>LO-low dose remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dose remifentanil (LO, 0.1 micrograms/kg/mL),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HI-high dose remifentanil with placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HN-high dose remifentanil with ultra-low dose naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>0.1 micrograms/kg/mL</description>
    <arm_group_label>LO-low dose remifentanil</arm_group_label>
    <other_name>LO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil+ Placebo</intervention_name>
    <description>high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)</description>
    <arm_group_label>HI-high dose remifentanil with placebo</arm_group_label>
    <other_name>HI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil +ultra-low dose naloxone</intervention_name>
    <description>high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone</description>
    <arm_group_label>HN-high dose remifentanil with ultra-low dose naloxone</arm_group_label>
    <other_name>HN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who provide written informed consent.

          -  Age 18 years old or older (no upper age limit for inclusion)

          -  Gender: male or female.

          -  Surgery: Posterior spinal fusions

        Exclusion Criteria:

          -  Allergy to opiates

          -  Chronic pain other than the primary indication for surgery

          -  Psychiatric illness

          -  History of substance abuse problem including alcohol &amp;/or cannabis

          -  BMI &gt; 35

          -  Subjects under 18 years of age.

          -  Subject without the capacity to give written informed consent. 8. Female subjects who
             are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariana Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Clinical Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariana Nelson, MD</last_name>
    <phone>714-456-5059</phone>
    <email>arianamn@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Cahill, PhD</last_name>
    <phone>949-824-5267</phone>
    <email>cmcahill@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael-David Calderon, BS</last_name>
      <phone>714-456-7800</phone>
      <phone_ext>2464</phone_ext>
      <email>mccalder@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Ariana Nelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Cahill, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bekhit MH. Opioid-induced hyperalgesia and tolerance. Am J Ther. 2010 Sep-Oct;17(5):498-510. doi: 10.1097/MJT.0b013e3181ed83a0.</citation>
    <PMID>20844348</PMID>
  </reference>
  <reference>
    <citation>Lin SL, Tsai RY, Shen CH, Lin FH, Wang JJ, Hsin ST, Wong CS. Co-administration of ultra-low dose naloxone attenuates morphine tolerance in rats via attenuation of NMDA receptor neurotransmission and suppression of neuroinflammation in the spinal cords. Pharmacol Biochem Behav. 2010 Aug;96(2):236-45. doi: 10.1016/j.pbb.2010.05.012. Epub 2010 May 15.</citation>
    <PMID>20478329</PMID>
  </reference>
  <reference>
    <citation>King T, Ossipov MH, Vanderah TW, Porreca F, Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals. 2005;14(4):194-205. Review.</citation>
    <PMID>16215302</PMID>
  </reference>
  <reference>
    <citation>Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth Analg. 1998 Jun;86(6):1307-11.</citation>
    <PMID>9620525</PMID>
  </reference>
  <reference>
    <citation>Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, Fletcher D, Chauvin M. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000 Aug;93(2):409-17.</citation>
    <PMID>10910490</PMID>
  </reference>
  <reference>
    <citation>Hansen EG, Duedahl TH, Rømsing J, Hilsted KL, Dahl JB. Intra-operative remifentanil might influence pain levels in the immediate post-operative period after major abdominal surgery. Acta Anaesthesiol Scand. 2005 Nov;49(10):1464-70.</citation>
    <PMID>16223391</PMID>
  </reference>
  <reference>
    <citation>Ma JF, Huang ZL, Li J, Hu SJ, Lian QQ. [Cohort study of remifentanil-induced hyperalgesia in postoperative patients]. Zhonghua Yi Xue Za Zhi. 2011 Apr 12;91(14):977-9. Chinese.</citation>
    <PMID>21609550</PMID>
  </reference>
  <reference>
    <citation>Cahill CM, Holdridge SV, Morinville A. Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci. 2007 Jan;28(1):23-31. Epub 2006 Dec 5. Review.</citation>
    <PMID>17150262</PMID>
  </reference>
  <reference>
    <citation>Holdridge SV, Armstrong SA, Taylor AM, Cahill CM. Behavioural and morphological evidence for the involvement of glial cell activation in delta opioid receptor function: implications for the development of opioid tolerance. Mol Pain. 2007 Mar 12;3:7.</citation>
    <PMID>17352824</PMID>
  </reference>
  <reference>
    <citation>Yalcin N, Uzun ST, Reisli R, Borazan H, Otelcioglu S. A comparison of ketamine and paracetamol for preventing remifentanil induced hyperalgesia in patients undergoing total abdominal hysterectomy. Int J Med Sci. 2012;9(5):327-33. doi: 10.7150/ijms.4222. Epub 2012 Jun 20.</citation>
    <PMID>22745573</PMID>
  </reference>
  <reference>
    <citation>Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI, Chauvin M. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005 Jul;103(1):147-55.</citation>
    <PMID>15983467</PMID>
  </reference>
  <reference>
    <citation>Song JW, Lee YW, Yoon KB, Park SJ, Shim YH. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy. Anesth Analg. 2011 Aug;113(2):390-7. doi: 10.1213/ANE.0b013e31821d72bc. Epub 2011 May 19.</citation>
    <PMID>21596876</PMID>
  </reference>
  <reference>
    <citation>Aguado D, Abreu M, Benito J, Garcia-Fernandez J, Gómez de Segura IA. Effects of naloxone on opioid-induced hyperalgesia and tolerance to remifentanil under sevoflurane anesthesia in rats. Anesthesiology. 2013 May;118(5):1160-9. doi: 10.1097/ALN.0b013e3182887526.</citation>
    <PMID>23407105</PMID>
  </reference>
  <reference>
    <citation>Kraemer WJ, Joseph MF, Volek JS, Hoffman JR, Ratamess NA, Newton RU, Fragala MS, French DN, Rubin MA, Scheett TP, McGuigan MR, Thomas GA, Gomez AL, Häkkinen K, Maresh CM. Endogenous opioid peptide responses to opioid and anti-inflammatory medications following eccentric exercise-induced muscle damage. Peptides. 2010 Jan;31(1):88-93. doi: 10.1016/j.peptides.2009.09.031. Epub 2009 Oct 2.</citation>
    <PMID>19800931</PMID>
  </reference>
  <reference>
    <citation>Luginbühl M, Gerber A, Schnider TW, Petersen-Felix S, Arendt-Nielsen L, Curatolo M. Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg. 2003 Mar;96(3):726-32, table of contents.</citation>
    <PMID>12598253</PMID>
  </reference>
  <reference>
    <citation>Sen H, Sizlan A, Yanarates O, Emirkadi H, Ozkan S, Dagli G, Turan A. A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy. Anesth Analg. 2009 Nov;109(5):1645-50. doi: 10.1213/ANE.0b013e3181b65ea0.</citation>
    <PMID>19843803</PMID>
  </reference>
  <reference>
    <citation>Xuerong Y, Yuguang H, Xia J, Hailan W. Ketamine and lornoxicam for preventing a fentanyl-induced increase in postoperative morphine requirement. Anesth Analg. 2008 Dec;107(6):2032-7. doi: 10.1213/ane.0b013e3181888061.</citation>
    <PMID>19020155</PMID>
  </reference>
  <reference>
    <citation>López-Álvarez S, Mayo-Moldes M, Zaballos M, Iglesias BG, Blanco-Dávila R. Esmolol versus ketamine-remifentanil combination for early postoperative analgesia after laparoscopic cholecystectomy: a randomized controlled trial. Can J Anaesth. 2012 May;59(5):442-8. doi: 10.1007/s12630-012-9684-x. Epub 2012 Mar 2.</citation>
    <PMID>22383085</PMID>
  </reference>
  <reference>
    <citation>Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schüttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003 Jul;99(1):152-9.</citation>
    <PMID>12826855</PMID>
  </reference>
  <reference>
    <citation>Engelhardt T, Zaarour C, Naser B, Pehora C, de Ruiter J, Howard A, Crawford MW. Intraoperative low-dose ketamine does not prevent a remifentanil-induced increase in morphine requirement after pediatric scoliosis surgery. Anesth Analg. 2008 Oct;107(4):1170-5. doi: 10.1213/ane.0b013e318183919e.</citation>
    <PMID>18806023</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Ariana Nelson</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

